Healthcare Professionals
Overview
ATERONON™ is a new ‘one-a-day’ natural supplement of 7mg patented, highly bioavailable lycopene.
ATERONON™, through clinical studies, has been shown to significantly reduce the oxidation of LDL cholesterol, recognised as one of the principal causes of astherosclerotic plaque formation. This may provide important information towards a targeted reduction of risk of heart attack and stroke.
Each capsule contains 7mg patented, highly bioavailable lycopene.
As a natural formulation, it is possible to take ATERONON™ alongside prescribed medication and other supplements.*
ATERONON™ is designed to be taken on an on-going basis in order to help maintain bioavailable levels of lycopene in the body that will continue to inhibit the oxidation of LDL cholesterol, which helps reduce the risk of plaque build-up in the arteries.
It is a natural product and is not known to have any side effects. It is not suitable for those with allergies to tomato, why protein or soy.
Summary:
- The Mediterranean diet is associated with increased protection against heart attack and stroke
- ATERONON™ is based on one of the main active components of the Mediterranean diet, lycopene, which has been shown to reduce the oxidation of LDL dramatically
- ATERONON™ delivers lycopene in a form that can reach optimum sustainable levels in the blood with a once-daily capsule
- ATERONON™ is a food grade product that has not been associated with any adverse effects in either healthy individuals or patients with cardiovascular disease alike
- ATERONON™ is not suitable for individuals with food allergies to, or intolerance of, tomatoes, milk and soya derivatives
- The ability of ATERONON™ to help inhibit LDL oxidation, recognised as a key step in the process of atherosclerosis, is a new piece of information towards the quest to reduce the risks of heart attack and stroke and, possibly, other atherosclerotic plaque-based conditions such as dementia and age-related macular degeneration.
Background:
ATERONON™ has been developed by Cambridge Theranostics, working with innovations originally identified by food company Nestle. Cambridge Theranostics is a bio-technology spin-out company from Cambridge University, originally funded by the British Heart Foundation.
ATERONON™ is produced to GMP standards in Milan, Italy.